Barclays analyst Leon Wang lowered the firm’s price target on MoonLake Immunotherapeutics to $55 from $59 and keeps an Equal Weight rating on the shares. The analyst says Argo “has some bright spots” but is overall comparable to Bime.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MLTX:
- MoonLake announces landmark Phase 2 results for Nanobody sonelokimab
- MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
- MoonLake Immunotherapeutics initiated with a Buy at Stifel
- MoonLake announces full dataset from 24-week MIRA clinical trial
- MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
Questions or Comments about the article? Write to editor@tipranks.com